Tiansheng Pharmaceutical Group Co Ltd - Asset Resilience Ratio
Tiansheng Pharmaceutical Group Co Ltd (002872) has an Asset Resilience Ratio of -3.12% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Tiansheng Pharmaceutical Group Co Ltd to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2023)
This chart shows how Tiansheng Pharmaceutical Group Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Tiansheng Pharmaceutical Group Co Ltd's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down Tiansheng Pharmaceutical Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Tiansheng Pharmaceutical Group Co Ltd debt and liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥-87.67 Million | -3.12% |
| Total Liquid Assets | CN¥-87.67 Million | -3.12% |
Asset Resilience Insights
- Limited Liquidity: Tiansheng Pharmaceutical Group Co Ltd maintains only -3.12% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Tiansheng Pharmaceutical Group Co Ltd Industry Peers by Asset Resilience Ratio
Compare Tiansheng Pharmaceutical Group Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for Tiansheng Pharmaceutical Group Co Ltd (2012–2023)
The table below shows the annual Asset Resilience Ratio data for Tiansheng Pharmaceutical Group Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | -3.12% | CN¥-87.67 Million ≈ $-12.83 Million |
CN¥2.81 Billion ≈ $411.32 Million |
-0.82pp |
| 2022-12-31 | -2.30% | CN¥-68.30 Million ≈ $-9.99 Million |
CN¥2.97 Billion ≈ $434.58 Million |
-4.93pp |
| 2021-12-31 | 2.63% | CN¥82.00 Million ≈ $12.00 Million |
CN¥3.12 Billion ≈ $456.56 Million |
+4.07pp |
| 2020-12-31 | -1.45% | CN¥-52.69 Million ≈ $-7.71 Million |
CN¥3.65 Billion ≈ $533.52 Million |
-0.19pp |
| 2019-12-31 | -1.26% | CN¥-55.16 Million ≈ $-8.07 Million |
CN¥4.39 Billion ≈ $642.61 Million |
-1.45pp |
| 2018-12-31 | 0.19% | CN¥8.96 Million ≈ $1.31 Million |
CN¥4.67 Billion ≈ $683.93 Million |
+1.28pp |
| 2016-12-31 | -1.09% | CN¥-37.04 Million ≈ $-5.42 Million |
CN¥3.39 Billion ≈ $496.35 Million |
+0.36pp |
| 2015-12-31 | -1.45% | CN¥-41.56 Million ≈ $-6.08 Million |
CN¥2.87 Billion ≈ $419.40 Million |
-0.66pp |
| 2014-12-31 | -0.79% | CN¥-19.60 Million ≈ $-2.87 Million |
CN¥2.50 Billion ≈ $365.12 Million |
-0.38pp |
| 2013-12-31 | -0.41% | CN¥-8.82 Million ≈ $-1.29 Million |
CN¥2.16 Billion ≈ $315.92 Million |
-0.08pp |
| 2012-12-31 | -0.33% | CN¥-5.70 Million ≈ $-834.25K |
CN¥1.74 Billion ≈ $255.19 Million |
-- |
About Tiansheng Pharmaceutical Group Co Ltd
Tiansheng Pharmaceutical Group Co., Ltd. engages in the pharmaceutical manufacturing and circulation activities. It offers products in various categories, including respiratory, cardiovascular and cerebrovascular, urinary system, gynecological, orthopedic, cardiology, diabetes, anesthetic, and others. It also provides traditional Chinese medicines and glucose injection. The company was founded in… Read more